Figure 5.
Figure 5. Effect of combined hirudin treatment and PAR-2 deficiency. (A) Survival of LPS-treated PAR-2+/+ mice with saline (solid line; n = 10), LPS-treated PAR-2+/+ mice with hirudin (dashed line; n = 17), and LPS-treated PAR-2–/– mice with hirudin (dotted line; n = 17). Hirudin statistically increased the survival time of PAR-2+/+ mice (P = .0001) and PAR-2–/– mice (P = .0001) compared with saline-treated PAR-2+/+ mice. The difference in survival between PAR-2+/+ and PAR-2–/– mice treated with hirudin is also statistically significant (P = .037). (B) LPS-induced IL-6 expression (8 hours) in PAR-2+/+ and PAR-2–/– mice treated with either saline or hirudin. Data are shown as mean ± SE (more than 6 mice per group).

Effect of combined hirudin treatment and PAR-2 deficiency. (A) Survival of LPS-treated PAR-2+/+ mice with saline (solid line; n = 10), LPS-treated PAR-2+/+ mice with hirudin (dashed line; n = 17), and LPS-treated PAR-2–/– mice with hirudin (dotted line; n = 17). Hirudin statistically increased the survival time of PAR-2+/+ mice (P = .0001) and PAR-2–/– mice (P = .0001) compared with saline-treated PAR-2+/+ mice. The difference in survival between PAR-2+/+ and PAR-2–/– mice treated with hirudin is also statistically significant (P = .037). (B) LPS-induced IL-6 expression (8 hours) in PAR-2+/+ and PAR-2–/– mice treated with either saline or hirudin. Data are shown as mean ± SE (more than 6 mice per group).

Close Modal

or Create an Account

Close Modal
Close Modal